Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition
Anlotinib alleviates MAILD progression by inhibiting the NETs-PI3K/Akt axis and subsequent EMT, providing a theoretical basis for drug repurposing and supporting its clinical translation potential in MAILD.
Authors
- Zhen Guo (ORCID: https://orcid.org/0000-0002-1364-3190)
- Sigong Zhang (ORCID: https://orcid.org/0000-0001-7793-9882)
- Huili Lu (ORCID: https://orcid.org/0000-0002-8748-7899)
- Yingyue Feng
- Qiang Su (ORCID: https://orcid.org/0000-0002-5852-4582)
- Hui Zhong Chai
- Xi Cui
- Jiarui Zhu
- Jumei Yang
Institutions
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- RMD Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-006443
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00